TNFRSF18 and neoplasm: Given that Th1 CD4+ T cells are known to provide key activating signals to myeloid lineage cells, we hypothesized that the anti-GITR (1)/SRS treatment resulted in downstream activation of intratumoral resident and infiltrating myeloid-derived cells that ultimately contributed to the anti-tumor effect.